Thymosin-alpha-1
Thymalfasin, Zadaxin, Thymosin Ī±1
A synthetic 28-amino acid peptide that enhances immune function by modulating T-cell activity, used for viral infections and immunodeficiencies.
Unknown
PHASE2
NCT02976740
SBRT Combination With rhGM-CSF and TĪ±1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy
The First Affiliated Hospital of Xiamen University
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT03659578
Study of Thymosin Ī±1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer
Sun Yat-sen University
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE2
NCT06573398
Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC
Ruijin Hospital
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT02366208
Phase II Trial for Combination Treatment of PEG-TĪ±1 and Adefovir for HBeAg Positive Chronic Hepatitis B
Jiangsu Hansoh Pharmaceutical Co., Ltd.
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT06461910
Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
Zekuan Xu
INTERVENTIONAL
Updated Dec 15, 2025
Unknown
PHASE1, PHASE2
NCT02906163
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
SciClone Pharmaceuticals
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT06584006
Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors
The First Affiliated Hospital of Xiamen University
INTERVENTIONAL
Updated Dec 15, 2025
Unknown
PHASE3
NCT02127268
Thymosin-Ī±1 in Cancer-Related Fatigue
Zhigang Zhang
INTERVENTIONAL
Updated Dec 15, 2025
Terminated
PHASE2
NCT04487444
Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection
Rhode Island Hospital
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
NA
NCT06598839
Immuno-effect of TĪ±1 for Stage I NSCLC
Yousheng Mao
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
NCT04901104
Long-term Prognosis of Patients With Sepsis After Immunotherapy
Sun Yat-sen University
OBSERVATIONAL
Updated Dec 15, 2025
Recruiting
NA
NCT06401447
TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma
Fudan University
INTERVENTIONAL
Updated Dec 15, 2025
Unknown
PHASE4
NCT02281266
Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection
Jia Fan
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE2
NCT06056804
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
Beijing Friendship Hospital
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1, PHASE2
NCT00197860
Dendritic Cell Based Therapy of Renal Cell Carcinoma
Inge Marie Svane
INTERVENTIONAL
Updated Dec 15, 2025
Withdrawn
PHASE2
NCT02535988
Abscopal Effect for Metastatic Colorectal Cancer
Zhejiang Provincial People's Hospital
INTERVENTIONAL
Updated Dec 15, 2025
Unknown
PHASE4
NCT04524169
Immunotherapy for Elderly Patients With Chronic Osteoporotic Pain
RenJi Hospital
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE4
NCT02473406
Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis
Weiqin Li
INTERVENTIONAL
Updated Dec 15, 2025
Unknown
PHASE4
NCT05658692
Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome
Second Affiliated Hospital, School of Medicine, Zhejiang University
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1, PHASE2
NCT02646189
Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients
Replicor Inc.
INTERVENTIONAL
Updated Dec 15, 2025